C12N 2770/20061
Methods of inactivation or attenuation
C12N2770/20061 (Methods of inactivation or attenuation) appears on 56 US grants and 101 published applications in this corpus.
Search patents in C12N- Granted patents
- 56
- Published applications
- 101
- Assignees
- 72
- Inventors
- 240
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 5 |
| 2005 | 0 | 0 |
| 2006 | 1 | 4 |
| 2007 | 3 | 2 |
| 2008 | 4 | 2 |
| 2009 | 1 | 1 |
| 2010 | 1 | 3 |
| 2011 | 0 | 6 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 2 | 1 |
| 2015 | 2 | 3 |
| 2016 | 2 | 3 |
| 2017 | 4 | 10 |
| 2018 | 5 | 6 |
| 2019 | 5 | 4 |
| 2020 | 2 | 1 |
| 2021 | 5 | 3 |
| 2022 | 4 | 8 |
| 2023 | 1 | 11 |
| 2024 | 3 | 10 |
| 2025 | 4 | 12 |
| 2026 | 2 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- System for producing and delivering contactless veterinary passive immunization3 Mar 2026US 12,564,627 B2Perumala Holdings, LLC
- Particles, DNA and RNA27 Jan 2026US 12,533,406 B2Novoscope IP Limited
- Viral vaccines and methods of forming the same7 Oct 2025US 12,435,317 B2NDSU Research Foundation
- Attenuated IBV with extended cell culture and tissue tropism2 Sep 2025US 12,403,191 B2Boehringer Ingelheim Vetmedica GmbH
- Viral preparations and methods for treating and modulating mitochondrial effects of coronavirus infections13 May 2025US 12,297,460 B1
- Antiviral agent, pharmaceutical composition for treating or preventing viral infection, kit for evaluating risk of viral infection becoming severe, and method for evaluating risk of viral infection becoming severe27 Aug 2026US 2026/0248897 A1Tohoku University
- Treatment using a one-to-stop attenuated sars-cov-2 virus7 May 2026US 2026/0124293 A1Institut FüR Virologie Und Immunologie (Ivi)
- Method for manufacturing inactivated sars-cov-2 vaccine, inactivated sars-cov-2 vaccine, method for purifying sars-cov-2 or inactivated sars-cov-2, and sars-cov-2 antigen composition or inactivated sars-cov-2 antigen composition12 Feb 2026US 2026/0041762 A1KM Biologics Co., Ltd.
- Live-attenuated sars-cov-2 vaccine23 Oct 2025US 2025/0325653 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Viral preparations and methods for treating and modulating mitochondrial effects of coronavirus infections.23 Oct 2025US 2025/0327038 A1
Most cited
By later US patents
- Binding molecules against SARS-coronavirus and uses thereof58US 7,696,330 B2Crucell Holland B. V. · 2010
- Coronavirus20US 10,130,701 B2The Pirbright Institute · 2018
- Modulation of replicative fitness by deoptimization of synonymous codons20US 8,846,051 B2The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · 2014
- Method of preparing an attenuated transmissible gastroenteritis (TGE) virus strain for use in live vaccines19US 4,159,319 A1979
- Attenuated viruses useful for vaccines13US 9,476,032 B2The Research Foundation for The State University of New York · 2016